Opens in a new tab or window Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the ...

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

In a retrospective cohort study, ustekinumab and guselkumab show trends toward lower risk for herpes zoster in patients with ...

Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...

Two adalimumab biosimilars (Amjevita and Imraldi) worked as well for moderate to severe psoriasis as the original brand-name product (Humira) for patients either starting or switching treatment ...

That's not necessarily what the data say, but in the clinic, I feel like adalimumab is still a really great initial option." For patients with skin-only psoriasis and no insurance issues ...

For plaque psoriasis, you’ll start with a loading dose of 80 mg of Humira. One week after your loading dose, you’ll start taking 40 mg every other week. Humira is available in a starter kit ...

Symptoms can include itching, pain, or swelling. Humira can also cause new or worsen psoriasis, a condition Humira is approved to treat. Psoriasis is a skin condition that causes symptoms such as ...

Eli Lilly and Company, Corcept Therapeutics, and AbbVie are the three Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks represent the publicly ...

with the latter two rivalling Humira in indications such as rheumatoid arthritis and psoriasis. Kavya Gopal, head of specialty at Sandoz UK, said: “Biosimilars offer the NHS the potential to ...